Journal of Pediatric and Adolescent Gynecology
Volume 20, Issue 6 , Pages 325-331 , December 2007

The HPV Vaccine Mandate Controversy

  • Gillian Haber, MPH

      Affiliations

    • Robert Stempel School of Public Health, Florida International University, Miami, Florida
    • ,
  • Robert M. Malow, PhD

      Affiliations

    • Robert Stempel School of Public Health, Florida International University, Miami, Florida
    • ,
  • Gregory D. Zimet, PhD

      Affiliations

    • Indiana University School of Medicine, Indianapolis, Indiana, USA
    • Corresponding Author InformationAddress correspondence to: Gregory D. Zimet, PhD, Indiana University School of Medicine, 410 W. 10th St., HS1001, Indianapolis, IN 46202

References 

  1. Villa LL, Costa RLR, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95:1450
  2. Centers for Disease Control and Prevention: Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2007;56(No. RR-2):1
  3. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet. 2004;364:1757
  4. Colgrove J. The ethics and politics of compulsory HPV vaccination. N Engl J Med. 2006;355:2389
  5. Orenstein WA, Hinman AR. The immunization system in the United Status—the role of school immunization laws. Vaccine. 1999;17(Supplement):S19
  6. Hinman AR, Orenstein WA, Williamson DE, et al. Childhood immunization: Laws that work. J Law Med Ethics. 2002;30(Supplement):122
  7. Centers for Disease Control and Prevention: A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP); Part 1: Immunization of infants, children, and adolescents. MMWR. 2005;54(No. RR-16):1
  8. Davis MM, Gaglia MA. Associations of daycare and school entry vaccination requirements with varicella immunization rates. Vaccine. 2005;23:3053
  9. Goldstein ST, Alter MJ, Williams IT, et al. Incidence and risk factors for acute hepatitis B in the United States, 1982–1998: Implications for vaccination programs. J Infect Dis. 2002;185:713
  10. Insurance Institute for Highway Safety: Child restraint laws as of March 2007. http://www.iihs.org/laws/state_laws/restrain2.html. 2007. Accessed March 19, 2007
  11. Omer SB, Pan WKY, Halsey NA, et al. Nonmedical exemptions to school immunization requirements. JAMA. 2006;296:1757
  12. Rota JS, Salmon DA, Rodewald LE, et al. Processes for obtaining nonmedical exemptions to state immunization laws. Am J Public Health. 2001;91:645
  13. Salmon DA, Teret SP, MacIntyre CR, et al. Compulsory vaccination and conscientious or philosophical exemptions: past, present, and future. Lancet. 2006;367:436
  14. Thompson JW, Tyson S, Card-Higginson P, et al. Impact of addition of philosophical exemptions on childhood immunization rates. Am J Prev Med. 2007;32:194
  15. Feikin DR, Lezotte DC, Hamman RF, et al. Individual and community risks of measles and pertussis associated with personal exemptions to immunization. JAMA. 2000;284:3145
  16. Lawson C: Introduced Version, Senate Bill 0327. Available: http://www.in.gov/legislative/bills/2007/IN/IN0327.1.html. Accessed March 20, 2007
  17. Association of Immunization Managers: Position statement: School and child care immunization requirements. Available: http://www.immunizationmanagers.org/pdfs/SchoolrequirementsFINAL.pdf. 2006. Accessed March 20, 2007
  18. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43
  19. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003;290:781
  20. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Nat Cancer Inst. 2004;96:604
  21. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. 2004;10:1915
  22. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13:28
  23. Pollack A: In need of a booster shot: Rising costs make doctors balk at giving vaccines. The New York Times 2007 Mar 24; Sec. B: 1(col. 2)
  24. Alter MJ, Hadler SC, Margolis HS, et al. The changing epidemiology of hepatitis B in the United States. JAMA. 1990;263:1218
  25. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (Types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006;118:2135
  26. Zimet GD, Liddon N, Rosenthal SL, et al. Chapter 24: Psychosocial aspects of vaccine acceptability. Vaccine. 2006;24S3:201
  27. Liddon N: Record of the meeting of the Advisory Committee on Immunization Practices: Behavioral issues related to HPV vaccination. http://www.cdc.gov/nip/ACIP/minutes/acip_min_feb06.pdf. 2006. Accessed March 22, 2007
  28. Lo B. HPV vaccine and adolescents' sexual activity. BMJ. 2006;332:1106
  29. Cuschieri KS, Horne AW, Szarewski A, et al. Public awareness of human papillomavirus. J Med Screen. 2006;13:201
  30. Abma JC, Martinez GM, Mosher WD, et al. Teenagers in the United States: Sexual activity, contraceptive use, and childbearing, 2002. Vital Health Stat. 2004;23(24):1
  31. Kirby D. The impact of schools and school programs upon adolescent sexual behavior. J Sex Res. 2002;39:27
  32. Vlahov D, Safaien M, Lai S, et al. Sexual and drug risk-related behaviours after initiating highly active antiretroviral therapy among injection drug users. AIDS. 2001;15:2311
  33. Diamond C, Richardson JL, Milam J, et al. Use of and adherence to antiretroviral therapy is associated with decreased sexual risk behavior in HIV clinic patients. J Acquir Immune Defic Syndr. 2005;39:211
  34. Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy and sexual risk behavior. JAMA. 2004;292:224
  35. Kalichman SC, Eaton L, Cain D, et al. HIV treatment beliefs and sexual transmission risk behaviors among HIV positive men and women. J Behav Med. 2006;29:401
  36. Centers for Disease Control and Prevention: Impact of vaccines universally recommended for children—United States, 1900–1998. MMWR. 1999;48(12):243
  37. Centers for Disease Control and Prevention: Recommended immunization schedules for persons aged 0-18 years - United States, 2007. MMWR. 2007;55(Nos. 51&52):Q1–Q4
  38. Fife KH, Wheeler CM, Koutsky LA, et al. Dose-ranging studies of the safety and immunogenicity of human papillomavirus type 11 and type 16 virus-like particle candidate vaccines in young healthy women. Vaccine. 2004;22:2943
  39. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271
  40. Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine. 2006;24:5571
  41. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet. 2006;367:1247
  42. Fraser C, Tomassini JE, Xi L, et al. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine. 2007;25:4324

 Disclosure: Dr. Zimet has been a speaker for Merck, and a consultant and speaker for SciMed and M2 Communications (medical education companies)

PII: S1083-3188(07)00172-6

doi: 10.1016/j.jpag.2007.03.101

Journal of Pediatric and Adolescent Gynecology
Volume 20, Issue 6 , Pages 325-331 , December 2007

Article Tools